Sparrow Pharmaceuticals
Targeted cardiometabolic therapeutics
- Headquarters
- Portland, Oregon
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- sparrowpharma.com
- Total Funding
- $217.0M
- Last Round
- $95.0M Series BSep 2025
- Rounds
- 4
About
Leveraging scientific insights into the intracellular regulation of cortisol, Sparrow is pioneering a precision approach to cardiometabolic disease. Their lead candidate, clofutriben, is a highly potent HSD-1 inhibitor designed to reduce elevated intracellular cortisol, addressing impaired glucose control in millions of patients with difficult-to-control type 2 diabetes.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sep 2025
Jul 2025
Apr 2024
May 2021
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biopharmaceutical services company
Specialty pharmaceutical company
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.